Arctic Bioscience – Board approval of share capital increase related to conversion of debt
Reference is made to the stock exchange release published by Arctic Bioscience 28th April 2025 regarding exercise of right to convert debt and corresponding issuance of new shares in Arctic Bioscience.
On 8 May 2025, the Board of Arctic Bioscience, on the basis of a board authorization granted by the Company’s General Meeting on 26th April 2024, resolved to increase the share capital from NOK 2 668 934 to NOK 2 685 934 by issuance of 170 000 new shares with a nominal value of NOK 0,10 per share, at a subscription price of NOK 3 per share, including a share premium of NOK 2,90 per share.
The total amount allocated as share premium is NOK 493 000. The total subscription amount is NOK 510 000. Following the registration of this share capital increase in the Norwegian Register of Business Enterprises, the Company’s share capital will be NOK 2 685 934 divided into 26 859 340 shares, each having a nominal value of NOK 0,10.
Minutes from Board Meeting and statement regarding capital increase are attached hereto.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Act.